Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

11.1%

1 terminated/withdrawn out of 9 trials

Success Rate

87.5%

+1.0% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 7 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
4(50.0%)
Phase 1
2(25.0%)
Early Phase 1
2(25.0%)
8Total
Phase 2(4)
Phase 1(2)
Early Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials
NCT03425201Phase 1Completed

Niraparib in Combination with Cabozantinib (XL184) in Patients with Advanced Urothelial Cancer (NICARAGUA)

Role: lead

NCT04160546Phase 2Active Not Recruiting

Study to Evaluate the Reinduction and Second Stop of TKI with Ponatinib in CML in Molecular Response (ResToP)

Role: lead

NCT05022797Phase 2Terminated

Reduction of MTX Levels After Glucarpidase Treatment in DLBCL Patients at Risk of CNS

Role: lead

NCT04483505Phase 1Completed

Rogaratinib, Palbociclib y Fulvestrant in Patients With Breast Cancer.

Role: lead

NCT03472274Phase 2Completed

Durvalumab (MEDI4736) and TREmelimumab in NEOadjuvant Bladder Cancer Patients (DUTRENEO)

Role: lead

NCT03469661Completed

Differential Diagnostic of Immune ThrombocytoPenia (ITP) and Myelodysplastic Syndrome (MDS)

Role: lead

NCT02802098Early Phase 1Completed

Abrogation of Chronic Monoclonal Antibody Treatment-induced T-cell Exhaustion With DURVALUMAB in Advanced HER-2 Negative Breast Cancer

Role: collaborator

NCT03448731Phase 2Completed

Skin Toxicity in Patients With Metastatic Colorectal Cancer Treated With Anti-EGFR and Chemotherapy (DERMIA)

Role: lead

NCT02806817Early Phase 1Completed

ME-344 in Early HER2-negative Breast Cancer With Antiangiogenic-induced Mitochondrial Metabolism

Role: collaborator

All 9 trials loaded